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Abstract
Purpose: The G-protein–coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) and its ligand
peptide adrenomedullin (encoded by ADM gene) are implicated in tumor angiogenesis in mouse models
but poorly defined in human cancers. We therefore investigated the diagnostic/prognostic use for CLR in
human tumor types thatmay rely on adrenomedullin signaling and in clear cell renal cell carcinoma (RCC),
a highly vascular tumor, in particular.
Experimental Design: In silico gene expression mRNA profiling microarray study (n¼ 168 tumors) and
cancer profiling cDNAarray hybridization (n¼ 241 pairs of patient-matched tumor/normal tissue samples)
were carried out to analyze ADM mRNA expression in 13 tumor types. Immunohistochemistry on tissue
microarrays containing patient-matched renal tumor/normal tissues (n¼ 87 pairs) was conducted to study
CLR expression and its association with clinicopathologic parameters and disease outcome.
Results: ADM expression was significantly upregulated only in RCC and endometrial adenocarcinoma
compared with normal tissue counterparts (P < 0.01). CLR was localized in tumor cells and vessels in RCC
and upregulated as compared with patient-matched normal control kidney (P < 0.001). Higher CLR
expression was found in advanced stages (P < 0.05), correlated with high tumor grade (P < 0.01) and
conferred shorter overall survival (P < 0.01).
Conclusions: In human tissues ADM expression is upregulated in cancer type–specific manner,
implicating potential role for adrenomedullin signaling in particular in RCC, where CLR localization
suggests autocrine/paracrine mode for adrenomedullin action within the tumor microenvironment. Our
findings reveal previously unrecognized CLR upregulation in an autocrine loop with adrenomedullin in
RCCwith potential application for this GPCRas a target for future functional studies anddrug development.
Clin Cancer Res; 19(20); 5740–8. 2013 AACR.
Introduction
Adrenomedullin (encoded by an ADM gene) is a multi-
functional peptide involved in cellular proliferation,
survival, and angiogenesis (1, 2). Whilst the role of adre-
nomedullin in tumor biology has been established from
studies using in vitro and mouse models and although
ADM gene expression is known to be upregulated by
hypoxia (a typical feature of solid tumors; refs. 3–5), there
is a general lack of information about the expression of
adrenomedullin receptors in human cancers and its cor-
relation with the disease outcome in particular (reviewed
in ref. 4).
In vitro, adrenomedullin mediates its activities through
binding to G-protein–coupled receptor (GPCR) calcitonin-
like receptor (CLR, encoded by theCALCRL gene; refs. 6, 7).
The GPCRs are the largest family of cell surface molecules
involved in signal transduction and they control key phys-
iologic functions, including regulation of blood pressure,
immune systemactivity, and inflammation. These receptors
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are involved in some of themost prevalent human diseases,
as reflected by the fact that GPCRs directly or indirectly
represent the targets of 50% to 60% of all current ther-
apeutic agents (8–10). For example, the analgesic drugs
codeine and morphine target opioid receptors in the
nervous system and the GPCR antagonist zibotentan
(ZD4054) targets the endothelin A receptor in solid
tumors (9, 11). Recently, some GPCRs, such as chemo-
kine and prostaglandin receptors, have emerged as crucial
players in tumor growth and metastasis, suggesting their
importance in initiation and progression of cancer in
humans (4, 11, 12).
In the present study, we tested the hypothesis that
GPCR CLR may be important in tumor biology in man
and could play a role in some human cancers. Our aims
were to determine those tumor types that may rely on
adrenomedullin, examine the pattern and level of expres-
sion of adrenomedullin receptor CLR in a prototypical
example, and conduct a clinicopathologic analysis to
assess its diagnostic and/or prognostic use. We therefore
carried out a large-scale in silico gene expression (mRNA
profiling) microarray study coupled with cancer profiling
cDNA array hybridization and identified tumors that had
upregulated ADM expression compared with patient-
matched normal tissue counterparts. Our data showed
that ADM expression was significantly upregulated only
in clear cell renal cell carcinoma (RCC) and endometrial
adenocarcinoma (P < 0.01) but not in other tumor types,
suggesting that in human tissues/organs it is upregulated
in cancer type–specific manner. We then focused on RCC
as potentially an adrenomedullin signaling–driven tumor
and, by using immunohistochemistry and a tissue micro-
array (TMA) approach, analyzed CLR expression in a large
cohort of patient-matched paired carcinoma and normal
kidney tissue samples. Our data showed that CLR was
localized in tumor cells and tumor vessels and that its
expression was upregulated in RCC, when compared with
patient-matched controls. Moreover, CLR expression was
higher in advanced stages and correlated with tumor
grade and overall patient survival. Our findings suggest
that GPCR CLR has clinical significance in RCC as a
promising immunohistochemical biomarker of disease
outcome and as a potential molecular target for thera-
peutic agents.
Materials and Methods
Please see details of the following methods in the Sup-
plementary Data: antibody, cell culture, SDS–PAGE and
immunoblotting, cancer profilingmicroarray hybridization
andNorthern blotting, RNA isolation, cDNA synthesis, and
quantitative real-time PCR (qRT-PCR).
GeneChip human genome array analysis
Public Affymetrix GeneChip HG-U133plus2 arrays data
for 11 carcinoma types (n ¼ 168 samples) were obtained
from the Expression Project for Oncology expO (http://
www.intgen.org/) via the National Center for Biotechno-
logy Information (NCBI) Gene Expression Omnibus
(GEO) repository (http://www.ncbi.nlm.nih.gov/projects/
geo; accession GSE2109). Raw data were preprocessed and
normalized using Bioconductor software for R (13), and the
robust-multiarray algorithm (rma) as previously described
(14–16).
The cancer profiling microarray hybridization and
Northern blotting
The Cancer Profiling Microarray 7841 (cDNA microar-
ray), consisting of normalized paired cDNA samples (n ¼
241) generated from the total RNA of 13 organs (breast,
uterus, colon, stomach, ovary, lung, kidney, rectum, thy-
roid, prostate, cervix, small intestine, and pancreas) was
obtained from Clontech (http://www.clontech.com). Each
cDNA pair consisted of carcinoma and corresponding
organ-matched normal tissue samples obtained from the
same patient, represented the entire mRNA message
expressed in given tissues, and was used to provide com-
prehensive ADM gene–disease correlation data.
ADM cDNAwas cloned into TOPOvector (Promega) and
ubiquitin cDNAprobewas fromBDBiosciences. Insertswere
excised with restriction enzymes and labeled with 32P-dCTP
using the Megaprime DNA Labeling Kit (GE Healthcare).
The specificity of the probes was confirmed by Northern
blotting,whichwas conducted as previously described (17).
Cancer profilingmicroarraywas consequentiallyhybridized
with each individual probe according to the manufacturer’s
instructions. The microarray was exposed to Hyperfilm
(GE Healthcare) and subsequently to Phosphoscreen. The
hybridization signals were further analyzed using Image-
Quant software. Ratio of ADM:Ubiquitin was calculated to
determine the relative mRNA expression levels and jittered
dot-plot graphs were generated using GraphPad Prism
software.
Patients
A total of 131patientswith histologically confirmed renal
carcinoma from two centers [John Radcliffe Hospital,
Oxford, United Kingdom (cohort 1; n ¼ 113 patients) and
Canterbury District Health Board, Christchurch, New Zeal-
and (cohort 2; n¼ 18 patients)] were included in this study.
Baseline histologic characteristics on all analyzed renal
tissue samples from cohort 1 (used for immunohisto-
chemical analysis as described later) and the information
on age and tumor characteristics (e.g., stage, grade, size, etc.)
for patients with RCC are provided in Tables 1 and 2,
Translational Relevance
Renal cancer is often resistant to conventional system-
ic treatments or current targeted therapies. This study
reveals that G-protein–coupled receptor (GPCR) calcito-
nin receptor-like receptor (CLR) expression in renal cell
carcinoma (RCC) is associated with poor outcome for
patients’ survival. These findings suggest application of
CLR as a molecular target for therapeutic agents/drug
development, while avoiding adverse effects on normal
tissues.
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respectively. The cause of death was obtained from the
OxfordCancer Registry from theOxfordCancer Intelligence
Unit (http://www.ociu.nhs.uk/; ref. 18). The median fol-
low-up time after nephrectomy was 43 months (ranging
from 1 to 296 months) and a mean overall survival was of
3.3 years. None of the patients received novel experimental
therapies, such as tumor vaccines or molecular targeted
medicine, nor had received any conventional treatment for
at least 6 months before the surgery. Overall survival was
defined as the time fromnephrectomy and cancer diagnosis
until death, the last time that the patient was known to be
alive, or until the end of follow-up. All hematoxylin and
eosin (H&E)–stained slides were reviewed by experienced
genitourinary pathologists and histologically classified
according to the World Health Organization (WHO) clas-
sification of tumors (19). Tumors were classified according
to the Fuhrman grade (20) and tumor—node—metastasis
(TNM) staging system (21) and data were deposited in the
Cancer Registry. T stage data were available for all patients,
whereas N and M staging data were not and therefore not
included in analysis. The samples from the cohort 2 patients
were collected for routine histologic evaluation and also for
reverse transcriptase PCR (RT-PCR) and qRT-PCR analysis
as described later.
All patients were confirmed to have sporadic disease
based on their medical records (obtained from Oxford
Cancer Registry), according to which no family history of
RCC was elucidated. The Central Oxfordshire Research
Ethics Committee (C00.147; C02.216) and Canterbury
Ethics Committee (V2-4 02.06.98-01.05.2002) approved
the use of all human tissues used in this study.
Tissue microarray and immunohistochemistry
TMA of 1 mm cores (from formalin-fixed, paraffin-
embedded specimens of renal carcinoma and normal tis-
sues) with 2-fold redundancy from 113 patients (including
87 pairs of patient-matched samples) of cohort 1 was
constructed (18) and 4 mm sections were cut. The presence
of all analyzed patient-matched normal and tumor tissue
samples on the same TMA section enabled the performance
of immunostaining under standardized conditions and its
quantitative comparison. Immunohistochemical analysis
of CLR expression was conducted using previously charac-
terized rabbit polyclonal anti-human CLR antibody
LN1436 (22) and preimmune serum from the same rabbit,
in which the antibody was raised, as a control. Additional
control was conducted using primary antibody preincu-
bated with 10 mg/mL peptide, against which it was raised,
for 90 minutes at room temperature before immunostain-
ing. Scoring of the intensity and proportion of tumor or
normal epithelial cells was conducted by two independent
pathologists and on two independently immunostained
TMA using a semiquantitative analysis as described else-
where (23). Briefly, the intensity of the staining ["no stain-
ing" (0), "weak staining" (1), "moderate staining" (2), or
"strong staining" (3)] and the percentage of stained cells
[0%–10% (1), 10%–50% (2), 51%–80% (3), or 81%–
100% (4)] were determined. Intensity was multiplied by
percentage to obtain "CLR intensity and percentage score"
for each tissue sample on TMA. The scoring of the intensity
(but not the percentage) of the CLR immunoreactivity in
tumor vessels or normal vessels was conducted following
the same approach.
RNA isolation, cDNA synthesis, RT-PCR, and qRT-PCR
were conducted as previously described (17, 24) using
tissue samples collected into the liquid nitrogen and stored
at 80C. For qRT-PCR, the following primer/probe kits
were used: Hs00181605_m1 (ADM) and Hs99999903_m1
(ACTB; both from Applied Biosystems). Relative quantifi-
cation of gene expression was conducted using previously
described method (25), based on the mean value of qRT-
PCR reactions carried out in triplicate. Human ACTB was
used as a reference gene to normalize for differences in the
amount of total RNA in each sample. The comparator for
the clinical samples was the median from normal kidney
samples.
Table 2. Clinicopathologic characteristics of
RCC patients
Age, y (median  SD) 62.6  10.7
Gender (male/female), n 31/51
T stage (TNM system), n
T1 28
T2 19
T3 40
T4 0
Grade (Fuhrman), n
G1 14
G2 49
G3 15
G4 8
Tumor size, cm (mean  SD) 8.0  3.39
Follow up, median (range), d 43.4 (0.1–296.2)
Mortality information renal
cancer-related death, n (%)
43 (50%)
Table 1. Histologic characteristics of analyzed
renal tumor tissue samples
Histology
Number of tumor
(paired) samplesa
Clear cell RCC (RCC) 87 (69)
Papillary RCC (PRCC) 3 (3)
Transitional cell carcinoma (TCC) 6 (0)
Oncocytoma 3 (3)
Sarcomatoid 8 (8)
Other (including chromophobe) 4 (4)
Total 113 (87)
aThe number of patient-matched normal kidney tissue sam-
ples is indicated in brackets.
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Statistical analysis
All statistical analyses were conducted using SPSS Statis-
tics software (version 16.0), GraphPad Prism or Microsoft
Excel computer programs. mRNA expression levels in
patient-matched normal and cancer tissues were analyzed
using Wilcoxon signed-rank t test. Analysis between the
level of CLR immunostaining in tumor cells on TMA and
various clinicopathologic parameters (patient’s age, tumor
size, histology, T stage, and Fuhrman grade) was conducted
using Spearman rank correlation or paired t tests depending
on the dataset as previously conducted in other studies (26,
27). For all tests, two-sided analysis was conducted and
actual P values are shown. P values of less than 0.05 were
considered statistically significant.
For the survival analysis, all immunostained on the
TMA RCC samples were divided into two categories
according to CLR immunostaining in tumor cells—"CLR
positive" (1–12) or "CLR negative" (0) based on intensity
and percentage score; or divided at the median into two
categories according to the staining in tumor/normal
vessels—"CLR high" and "CLR low." Kaplan–Meier
curves and log-rank Mantel–Cox test was used to estimate
the association of CLR expression levels in tumor cells or
tumor vessels with an overall survival to obtain protein-
disease outcome data based on available data for patients
with RCC (total n ¼ 87; Table 2). All survival analyses
refer to overall survival times, where time to death from
disease represents an event. Patients were censored in
survival according to the date last seen by a doctor as
indicated earlier. The median survival times and HRs
within each subgroup were estimated from Kaplan–Meier
curves.
Results
ADM expression in human tissues is upregulated in a
cancer type–specific manner
There was a significant heterogeneity of ADM expression
across 11 human tumor types studied here (Fig. 1A). The
highest (mean log2 value 11.5) levels were in RCC and the
lowest (mean log2 value 8) levels were in breast carcinoma,
that is, approximately 10-fold variation. Furthermore, ADM
expression was significantly altered only in three tumor types
out of 13 analyzed carcinomas (upregulated in kidney and
uterine tumors, whereas downregulated in breast carcinoma;
Fig. 1B; Supplementary Fig. S1). The highest upregulation of
ADMmRNA expression was found in RCC when compared
with paired normal kidney (Fig. 1C and Supplementary
Fig. S1) and this was confirmed by qRT-PCR using an
independent cohort of 18 pairs of patient-matched renal
carcinoma and normal control tissue samples (Fig. 1D).
CLR is expressed in tumor cells and tumor vessels in
RCC and terminally glycosylated in tumor tissues and
cell lines
CLR was variably expressed in tumor cells and tumor
vessels in RCC and in normal patient-matched tissue sam-
ples (n¼ 87 pairs, including 69 RCC cases) and in RCC cell
lines, as shown by immunohistochemistry and/or immu-
noblotting. CLR was localized in both tumor cells and
tumor vessels (Fig. 2 and Supplementary Fig. S2A and
S2B) and its expression was upregulated in renal tumors
in general and in individual types (Supplementary Fig. S3A
and S3B), including RCC (Fig. 3A), when compared with
control patient-matched normal tissues.
CLR was terminally but not core-glycosylated when
expressed in RCC tissues (Supplementary Fig. S4A). Fully
processed terminally glycosylated form of CLR is only
produced in the presence of the receptor activity modify-
ing proteins (RAMPs) and only in this particular form
this GPCR is expressed at the cell surface and can bind to
the ligand, that is, to be "functional" (28). Therefore, our
findings suggest that CLR is likely to be in its cell surface–
bound/functional form (6, 22, 28, 29), when expressed in
RCC tumor cells and tumor vessels in situ (Fig. 2 and
Supplementary Fig. S2). In vitro, CLR was also expressed
in some, but not all, renal tumor cell lines (Supplementary
Fig. S4B). We confirmed that the presence of terminally
glycosylated CLR in renal tumor tissues or cultured renal
tumor cell lines and primary microvascular endothelium
was associated with the expression of RAMP1, 2, and 3
mRNAs (Supplementary Fig. S5), which encode proteins
that facilitate terminal glycosylation and transport of the
CLR to the cell membrane (6).
CLR expression in tumor cells in RCC correlates with
tumor grade and patient survival rates
CLR expression in tumor cells (but not in tumor vessels)
was significantly higher (P<0.05) in advanced stages (II and
III; Supplementary Fig. S6) and correlated with high tumor
grade (P < 0.01), but not with tumor size or patient age
(Table 3). Furthermore, patients with RCC with CLR
expressed in tumor cells had significantly shorter overall
survival when compared with those with no CLR (with
median survival times of 543 and 784 days, respectively and
HR, 0.4182; P ¼ 0.01; Fig. 3B).
Discussion
Renal cancers account for 2% to 4%of cancers worldwide
(http://www.cancer.org). The 5-year survival of patients
with renal cancer is 40.5%, largely due to metastasis which
accompany 75% of the cases (30, 31). In these patients,
systemic or adjuvant treatments, such as conventional cyto-
toxic chemotherapy or cytokine immunotherapy, give a
sustained response rate of only 10% and they are associated
with considerable toxic effects (30–32). Recently, the unra-
veling of the hypoxic response in RCC through von Hippel-
Lindau (VHL)/hypoxia-inducible factor (HIF)–mediated
signaling has shown how its downstream pathways and
processes, such as angiogenesis, are integral to the patho-
genesis/progression of renal cancer (5). Indeed, tumor
responsiveness to the newer anticancer and antiangiogenic
drugs such as sorafenib, sunitinib, and bevacizumab, target-
ing vascular endothelial and/or platelet-derived growth
factor (VEGF and PDGF, respectively; both products of the
genes which are transcriptional targets of HIF) pathways,
showed the benefit of exploiting them for targeted therapy
GPCR CLR Expression Predicts RCC Patient Survival
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in human cancers, including RCC (33–36). Nevertheless, a
significant number of patients with RCC do not completely
respond (or become resistant) to these antiangiogenic or
current combination therapies, which often require long-
term administration for continued disease control and have
several adverse effects. This suggests that other molecular
pathways may be activated in this type of cancer and play a
significant role in its progression and also support the need
for the continued exploration of these pathways and prog-
nostic or predictivemarkers for this disease as well as for the
development of novel agents and new treatment combina-
tions (32).
Adrenomedullin signaling pathway(s) mediated by
GPCR CLR could be one such potentially significant axis
for therapeutic intervention in RCCdue to the upregulation
of ADM expression by hypoxia and HIF (similar to VEGF
and PDGF genes), and also because the role for adrenome-
dullin in tumor growth and angiogenesis has been already
established by studies using mouse xenografted tumor
models and in vitro assays (reviewed in refs. 3, 4). A recent
study suggested that signaling via CLR has potential role in
bypassing the normal requirement for VEGF signaling in
endothelial cells during embryogenesis (37). However,
while these observations pointed to a potential role for
adrenomedullin in tumor biology and angiogenesis, the
clinical significance or functional contribution of adreno-
medullin signaling to tumorigenesis in human tissues is as
yet poorly defined (reviewed in ref. 4). To date, studies in
man have been limited to measurements of ADM mRNA
levels (38, 39) or adrenomedullin peptide concentration in
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Figure 1. ADM mRNA expression in patient-matched renal carcinoma and normal tissues. GeneChip Human Genome Array data were obtained from the
ExpressionProject forOncology (expO) via theNCBIGEO repository (accessionGSE2109;n¼168covering 11most common typesof humancarcinomas). A,
ADM mRNA expression levels were compared and presented on the box (interquartiles) and whisker (95th percentiles) plots, showing log2 expression
of ADM probe 202912_at. B, ADM expression was studied using the cancer proﬁling cDNA microarray (Clonetics), which consists of normalized paired
normal and cancer cDNA samples (n¼ 241 pairs) generated from the total RNA of 13 organs (as labeled and speciﬁed later on the bottom cDNA microarray
image). The microarray was subsequently hybridized with ADM and ubiquitin probes labeled with 32P-dCTP, the speciﬁcity of which was conﬁrmed on
Northern blot, using RNA obtained from paired normal (lane N) and carcinoma (lane C) patient-matched tissue samples. The highest ADM mRNA
expression was found in renal tissues (boxed on top cDNAmicroarray image), where it was upregulated in carcinoma (right column, C), when compared with
normal tissue (left column, N) samples. C, the microarray was exposed to Phosphoscreen and hybridization signals were analyzed using ImageQuant
software. Ratio of ADM:ubiquitin was calculated to determine the relative ADM mRNA expression levels and to generate jittered dot-plot plot graph for
patient-matched normal and carcinoma renal cDNA samples (n¼ 20 pairs). Statistical analysis was conducted usingWilcoxon signed-rank test. Note that the
quantitative data and graphs for all other carcinoma types from the cDNAmicroarray are presented in the Supplementary Fig. S1. D,ADMmRNA upregulation
in renal cancers was conﬁrmed by qRT-PCR using an independent cohort of paired patient-matched normal and carcinoma RNA samples (n ¼ 18;
RCC, n ¼ 14; papillary, n ¼ 2; oncocytoma, n ¼ 2). Ratio of ADM:ACTB was calculated to determine relative quantity of ADMmRNA and shown on jittered
dot-plot graph for normal and carcinoma samples. Wilcoxon signed-rank test was used. C and D, actual P values are shown.
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blood and tissues (40) and to the use of few tumor cell lines
or a limited number of neoplastic tissues; all only occasion-
ally done with the comparison between the patient-
matched normal and cancer samples. The data about CLR
expression, including distribution/localization and presen-
tation at the cell surface in vivo, in human tumor tissues are
also very limited and have not been systematically studied
(22, 38, 41). In particular, there is a general lack of infor-
mation about the association of adrenomedullin and/or
CLR expression with disease outcome and patient survival
in various cancer types, including RCC. As a result, limited
data are available not only for the evaluation of a possible
role for adrenomedullin and CLR during initiation and
progression of cancer in humans but also for an overall
assessment of their value and potential in clinical oncology,
for example, for diagnostics, prognosis, and/or targeted
therapy (4, 29).
In the present study, by using large-scale in silico gene
expression data screening coupled to the analysis of patient-
matched carcinoma and normal tissue samples, we found
that ADMmRNA expression in human organs and tissues is
upregulated only in a small number of tumors and in RCC
in particular; in keeping with two previous studies of ADM
expression in renal cancer with combined numbers of 62
N
or
m
al
R
CC
PR
CC
TC
C
Sa
rc
om
at
oi
d
O
n
co
cy
to
m
a
CLR CLR
100 µm 50 µm 100 µm  
Control
Figure 2. CLR expression in tumor
cells and tumor vessels in renal
carcinoma. The renal cancer
proﬁling TMA included paired
carcinoma and corresponding
normal tissue samples from
individual patients (n ¼ 87;
including 69 RCC cases) as
described in the Materials
and Methods and Table 1.
CLR localization (CLR;
left column of images—at low
magniﬁcation and middle
column of images—at higher
magniﬁcation) was assessed by
immunohistochemistry using anti-
CLR antibody LN1436. Secondary
goat anti-rabbit antibody
conjugated to horseradish
peroxidase was used and
further detected with 3,30—
diaminobenzidine (DAB; brown).
Cell nuclei were counterstained
with hematoxylin (blue).
Immunostaining using primary
antibody preadsorbed with
peptide antigen, against which it
was raised, was used as a
control (Control; right). Note
that the receptor is localized
predominantly in the vessels
(arrows) in glomeruli and between
tubules in normal tissue (top) and in
carcinomas (RCC, clear cell;
PRCC, papillary carcinomas; TCC,
transitional cell carcinoma of the
renal pelvis) aswell as oncocytoma
and sarcomatoid renal cancers;
and also in normal epithelial cells
and in renal neoplastic cells (both
arrowheads). Note that one
example is given here for RCC,
although CLR expression levels
vary in tumor cells in this type of
renal cancer; to show this, six RCC
cases are presented in the
Supplementary Fig. S2.
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cases (38, 39). Furthermore, our TMA and immunoblotting
data showed that adrenomedullin receptor CLR is localized
both in tumor cells and tumor vessels and expressed in its
functional (i.e., terminally glycosylated/cell surface–
bound) form in renal carcinoma tissues. These findings
suggest a potent autocrine loop or paracrine mode for
adrenomedullin action and possibly biologically active in
vivo roles for this CLR-mediated signaling in both angio-
genesis and/or tumor cell biology within RCC microenvi-
ronment, especially upon upregulation of ADM expression.
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Figure 3. High CLR expression in tumor cells and tumor vessels in RCC compared with normal tissues and its association with patient survival. The
semiquantitative analysis of the TMA data for CLR immunostaining (as shown in Fig. 2) was used to provide comprehensive CLR protein-disease (RCC)
outcome correlation data. A, CLR expression in tumor cells and tumor vessels in RCC was compared with that in normal epithelial cells or vessels in
control histologically normal kidney tissue (n¼ 69 patient-matched paired tumor and corresponding control/normal tissue samples) as shown on bar graphs
(mean  SD). Statistical analysis was conducted using paired t test. B, Kaplan–Meier overall survival curve for patients with renal cancer subgrouped
according to CLR expression in tumor cells or tumor vessels in RCC. All samples used for the analysis were divided/stratiﬁed into two categories/groups
based on quantiﬁcation of CLR immunostaining as described in the Statistical Analysis: "CLR positive" and "CLR negative" for tumor cells and "CLR high"
and "CLR low" for tumor vessels. The representative images, showing variations in CLR expression levels in tumor cells in individual RCC cases, are
presented in the Supplementary Fig. S2. Log-rank Mantel–Cox test was used for the statistical analysis. A and B, actual P values and numbers of analyzed
pairs of patient-matched tissue samples or RCC cases are shown.
Table 3. Spearman-rank correlation analysis of CLR immunostaining in RCC tumor cells and tumor vessels
with some important clinicopathologic or prognostic parameters
Tumor cells Tumor vessels
Variables Spearman R 95% CI P Spearman R 95% CI P
Age 0.026 (0.19)–0.24 0.815 0.053 (0.27)–0.17 0.625
Grade (G1–4) 0.31 0.098–0.50 0.004 0.16 (0.37)–0.057 0.133
Tumor size 0.12 (0.10)–0.34 0.275 0.017 (0.24)–0.21 0.881
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We therefore hypothesized (and tested) that CLR might be
important in RCC progression.
In support of this hypothesis, we found that CLR expres-
sion in tumor cells is significantly upregulated compared
with patient-matched normal epithelial cells and that its
high levels strongly associate with advanced stages and
correlate with tumor grade as well as with shorter survival
of patients with RCC. To our knowledge, this is the first
report showing that in human cancers the adrenomedullin
receptor CLR has a prognostic value as the immunohisto-
chemical biomarker of patient survival. Another important
site for adrenomedullin action within the RCC microenvi-
ronment is tumor vessels, where CLR is also significantly
upregulated when compared with patient-matched normal
kidney vessels. We have previously shown that adrenome-
dullin interacts with endogenous CLR in cultured primary
human microvascular endothelial cells, which express this
GPCR in tissues, and induces their proliferation andmigra-
tion in vitro (22), suggesting the role for adrenomedullin
during angiogenesis and in vascular biology in general in
human organs. In the present study, despite the lack of
correlation of upregulated CLR expression in tumor vessels
with various clinicopathologic parameters and patients
survival, the increased levels of this GPCR might neverthe-
less have a direct impact on tumor angiogenesis—the hall-
mark of cancer progression in the kidney (5, 32, 35,
36, 42)—due to simultaneous upregulation in the expres-
sion of both the ligand and its receptor within the tumor
microenvironment, as revealed in this study. Alternatively,
because some of the RCC vessels may be lymphatics and
because adrenomedullin may play a role in lymphatic
endothelial cell biology (43–46), CLR can affect tumor
lymphangiogenesis (and possibly tumor spread via lym-
phatic vessels) and therefore further vessel subtyping may
provide additional prognostic information in the future.
It is widely acknowledged that the differential expres-
sion of a specific molecule in tumor compared with
normal tissues is often crucial for the development of
targeted therapies and strategies in cancer (47). Therefore,
upregulated (in an autocrine loop with adrenomedullin)
by RCC tumor cells and tumor vessels CLR has a potential
as a cell surface–presented molecular target for future
functional studies in renal cancer using already developed
range of modulators of adrenomedullin-induced effects
(and hence downstream signaling pathways mediated by
this GPCR within human tumor tissue), including anti-
bodies and peptide antagonists of adrenomedullin recep-
tors (4, 48, 49).
In summary, the present study reveals previously unrec-
ognized cancer type–specific upregulation of ADM expres-
sion in human tissues/organs and prognostic value for
adrenomedullin receptor CLR in RCC. Our findings suggest
the potential use for CLR as a novel target for future clinical
studies and drug development for the therapy for RCC, and
possibly other hypoxia-driven cancers. In particular, drug-
resistant RCC could be an idealmodel for further evaluating
the prognostic use of CLR as a biomarker in first-line as well
as refractory to antiangiogenic or combination treatments
patients and for investigating the potential role for adreno-
medullin- and CLR-mediated signaling in tumor cells and
tumor vessels resistance to conventional chemotherapy and
current targeted therapies.
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